Seattle biotech company PhaseRX is being bought by multinational drug commercialization company Roivant Sciences, according to an SEC filing. Roivant will pay $800,000 for “substantially all of [PhaseRX’s] assets” and… Read More
In May of last year, biotech company PhaseRX broke an unprecedented IPO drought in Seattle with its $18.5 million initial public offering. But just 19 months later, the company has filed… Read More
There weren’t many Seattle-area technology companies that completed IPOs in 2016, but it was enough to beat last year’s unprecedented drought. PhaseRx, Impinj, and Apptio went public this year. That’s up… Read More
Seattle-based biotech company PhaseRx develops drug candidates to treat rare, often life-threatening liver diseases, and one of their candidates just got a boost from the FDA. The company’s leading drug, called… Read More
Plenty of companies promise to change people’s lives by offering them something that was perhaps previously unavailable. As the founder, president and CEO of Seattle-based PhaseRx, Robert Overell thinks his company can bring… Read More
Wistar Kay, business development manager for the Washington State Department of Commerce, has announced her retirement effective Aug. 19, and Rob Fiddick has been named to take her place. The agency’s… Read More